Johnson & Johnson discontinues the Phase 3 SunRISe-2 trial for TAR-200 in bladder cancer, citing lack of superiority. Q3 ...

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug ...

The SWOG S1011 trial shows no survival benefit from extended lymphadenectomy in bladder cancer, revealing higher complications and mortality post-surgery.

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...

Final results from the SWOG S1011 randomized Phase III clinical trial, published in the New England Journal of Medicine, ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...

Results from cohort 2 of the TROPHY-U-01 study showed that sacitizumab govitecan led to rapid responses in patients with ...

The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...

(HealthDay News) — Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma (ccRCC) and ...